Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Group plc has announced a delay in the release of its preliminary financial results for the year ending December 31, 2024, now scheduled for June 6, 2025, due to additional audit time requested by the company’s auditors. The delay does not affect Avacta’s financial position or cash runway, and the company will conduct a live presentation for shareholders on the same day to discuss the results.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing advanced cancer therapies using its proprietary pre|CISION® platform. This platform targets tumor-specific proteases to deliver potent anti-cancer agents directly to tumors, minimizing damage to healthy tissues and offering advantages over traditional therapies.
Average Trading Volume: 2,006,177
Technical Sentiment Signal: Sell
Current Market Cap: £143M
For an in-depth examination of AVCT stock, go to TipRanks’ Stock Analysis page.